Department of Pathology, Klinikum Chemnitz gGmbH, Chemnitz, Germany.
Gastrointest Endosc. 2011 Feb;73(2):325-8. doi: 10.1016/j.gie.2010.10.026. Epub 2010 Dec 22.
EUS is an established method for staging of rectal cancer. Nevertheless, there are few data about the significance of infiltration depth measured by EUS.
Assessment of accuracy of T and N staging by EUS with attention to infiltration depth as provided by EUS.
Part retrospective, part prospective study.
Community and tertiary referral hospital, covering the period before neoadjuvant therapy for advanced rectal cancer was established.
Eighty-three patients (60% men) with untreated rectal cancer.
EUS examination.
We examined the correlation between EUS findings and postoperative histology. T3 cancers as diagnosed by EUS were classified into minimally invasive (1-2 mm) or advanced (>2 mm) tumors depending on the depth of infiltration beyond the muscularis propria.
Accuracy of T staging and N status was 76% and 63%, respectively. Overstaging by EUS was more common in minimally invasive T3 by EUS (uT3) (8 of 16 [50%]) compared with advanced uT3 tumors (1 of 24 [4%]) (P=.01). Accuracy of EUS discrimination between T1/2 and T3/4 in rectal cancer for all but minimally invasive uT3 rectal tumors was 88%.
Partly retrospective analysis.
EUS examination of rectal carcinoma determines T stage with high accuracy. Additionally, it provides information beyond T and N staging. The 50% probability of overstaging patients with minimally invasive uT3N0 by EUS may argue for managing these cancers as stage I disease, ie, to refer the patient for surgery without neoadjuvant therapy.
EUS 是一种用于直肠癌分期的成熟方法。然而,关于 EUS 测量的浸润深度的意义的数据很少。
评估 EUS 对 T 和 N 分期的准确性,并关注 EUS 提供的浸润深度。
部分回顾性,部分前瞻性研究。
社区和三级转诊医院,涵盖新辅助治疗前治疗晚期直肠癌的时期。
83 例未经治疗的直肠癌患者(60%为男性)。
EUS 检查。
我们检查了 EUS 结果与术后组织学之间的相关性。EUS 诊断的 T3 癌根据浸润超出肌层的深度分为微创(1-2mm)或进展(>2mm)肿瘤。
T 分期和 N 状态的准确性分别为 76%和 63%。EUS 对微创 uT3(8 例[50%])的过度分期比进展性 uT3 肿瘤(1 例[4%])更为常见(P=.01)。EUS 对除微创 uT3 直肠肿瘤外的所有 T1/2 和 T3/4 直肠肿瘤的 T 分期的鉴别准确性为 88%。
部分回顾性分析。
EUS 检查直肠癌的 T 分期具有很高的准确性。此外,它提供了 T 和 N 分期以外的信息。EUS 对微创 uT3N0 患者的过度分期率为 50%,这可能表明应将这些癌症作为 I 期疾病进行管理,即无需新辅助治疗即可将患者转介手术。